Drug advances in inflammatory bowel disease
R Alexander Speight and John C Mansfield
DOI: https://doi.org/10.7861/clinmedicine.13-4-378
Clin Med August 2013 R Alexander Speight
Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK
Roles: specialist registrar in gastroenterology
John C Mansfield
Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK
Roles: consultant gastroenterology
Article Tools
Drug advances in inflammatory bowel disease
R Alexander Speight, John C Mansfield
Clinical Medicine Aug 2013, 13 (4) 378-382; DOI: 10.7861/clinmedicine.13-4-378
Citation Manager Formats
Jump to section
- Article
- ABSTRACT
- Background
- The lack of efficacy of 5-aminosalicylic acids in Crohn's disease
- Controversy over the optimum dose of 5-aminosalicylic acids in ulcerative colitis
- A greater role for topical 5-aminosalicylic acids in treating ulcerative colitis
- The role of anti-TNFα drugs in Crohn's disease
- The concept of deep remission in Crohn's disease
- Evidence for the use of early immunosuppression in Crohn's disease
- The role of anti-TNFα treatment in ulcerative colitis
- The long-term safety of anti-TNFα treatment
- Summary
- References
- Figures & Data
- Info & Metrics
Related Articles
- No related articles found.
Cited By...
- No citing articles found.